Could an arthritis drug help fight pancreatic cancer?
NCT ID NCT04926467
First seen Nov 11, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This phase 2 trial is testing whether adding the drug anakinra (Kineret) to standard chemotherapy can improve outcomes for people with pancreatic cancer that can be surgically removed or is locally advanced. Anakinra is an anti-inflammatory drug typically used for rheumatoid arthritis. The study will enroll 24 adults and measure how well the treatment normalizes a key tumor marker (CA19-9) and improves survival. Participants will receive the drug combination before and after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anakinra (Kineret) plus chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
What this could lead to
If successful, this combination could improve survival rates and help more patients become eligible for surgery, potentially extending life for those with pancreatic cancer.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Anakinra can cause injection site reactions and increase infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.